nach oben

Clinical and Translational Oncology

Erschienen in:

24.05.2018 | Review Article

Cutaneous toxicities of new treatments for melanoma

verfasst von: A. Boada, C. Carrera, S. Segura, H. Collgros, P. Pasquali, D. Bodet, S. Puig, J. Malvehy

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients’ quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.CrossRefPubMed

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.CrossRefPubMed

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.CrossRefPubMed

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.CrossRefPubMed

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.CrossRefPubMed

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.CrossRefPubMed

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.CrossRefPubMed

Boada A. Toxicidad cutánea de los inhibidores del BRAF y del MEK. Piel. 2015;30(5):309–15.CrossRef

Hwang SJE, Anforth R, Carlos G, Fernandez-Peñas P. Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr. 2017;108(1):6–16.CrossRefPubMed

10.

Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.CrossRefPubMed

11.

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.CrossRefPubMedPubMedCentral

12.

Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480–1.CrossRefPubMed

13.

Brugière C, Stefan A, Morice C, Cornet E, Moreau A, Allouche S, et al. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. Br J Dermatol. 2014;171(6):1529–32.CrossRefPubMed

14.

Gelot P, Dutartre H, Khammari A, Boisrobert A, Schmitt C, Deybach J-C, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22(4):297–8.CrossRefPubMed

15.

Gabeff R, Dutartre H, Khammari A, Boisrobert A, Nguyen J-M, Quereux G, et al. Phototoxicity of B-RAF inhibitors: exclusively due to UVA radiation and rapidly regressive. Eur J Dermatol. 2015;25(5):452–6.PubMed

16.

Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol. 2013;31(13):e220–2.CrossRefPubMed

17.

Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26(6):1238–44.CrossRefPubMed

18.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.CrossRefPubMedPubMedCentral

19.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265–72.CrossRefPubMedPubMedCentral

20.

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–9.CrossRefPubMed

21.

Specchio F, Argenziano G, Tiodorovic-Zivkovic D, Moscarella E, Lallas A, Zalaudek I, et al. Dermoscopic clues to diagnose acantholytic dyskeratosis. Dermatol Pract Concept. 2015;5(1):59–60.CrossRefPubMedPubMedCentral

22.

Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014;150(3):307–11.CrossRefPubMed

23.

Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.CrossRefPubMed

24.

Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153–60.CrossRefPubMed

25.

Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, et al. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol. 2015;72(4):738–41.CrossRefPubMed

26.

Choy B, Chou S, Anforth R, Fernández-Peñas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493–7.CrossRefPubMed

27.

Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357–61.CrossRefPubMed

28.

Monfort J-B, Pagès C, Schneider P, Neyns B, Comte C, Bagot M, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22(5):399–401.CrossRefPubMed

29.

Mössner R, Zimmer L, Berking C, Hoeller C, Loquai C, Richtig E, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1797–806.CrossRefPubMed

30.

Yorio JT, Mays SR, Ciurea AM, Cohen PR, Wang W-L, Hwu W-J, et al. Case of vemurafenib-induced sweet’s syndrome. J Dermatol. 2014;41(9):817–20.CrossRefPubMed

31.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555–67.CrossRefPubMed

32.

Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR, Fearfield L. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol. 2014;170(4):997–9.CrossRefPubMed

33.

Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol. 2013;149(10):1242–3.CrossRefPubMed

34.

Adam A, Thomas L, Bories N, Zaharia D, Balme B, Freymond N, et al. Sarcoidosis associated with vemurafenib. Br J Dermatol. 2013;169(1):206–8.CrossRefPubMed

35.

Ma L, Dominguez AR, Collins GR, Kia KF, Cockerell CJ. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol. 2012;148(12):1428–9.CrossRefPubMed

36.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.CrossRefPubMedPubMedCentral

37.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.CrossRefPubMed

38.

Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.CrossRefPubMed

39.

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2015;121(1):60–8.CrossRefPubMed

40.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172(1):239–43.CrossRefPubMed

41.

Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316–21.CrossRefPubMed

42.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.CrossRefPubMedPubMedCentral

43.

Weeraratna AT. RAF around the edges—the paradox of BRAF inhibitors. N Engl J Med. 2012;366(3):271–3.CrossRefPubMed

44.

Wu JH, Cohen DN, Rady PL, Tyring SK. BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for a viral involvement, and perspectives on clinical management. Br J Dermatol. 2017;177(4):914–23.CrossRefPubMed

45.

Lallas A, Pyne J, Kyrgidis A, Andreani S, Argenziano G, Cavaller A, et al. The clinical and dermoscopic features of invasive cutaneous squamous cell carcinoma depend on the histopathological grade of differentiation. Br J Dermatol. 2015;172(5):1308–15.CrossRefPubMed

46.

Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007.CrossRefPubMed

47.

Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-Séguin N, Del Marmol V, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431–42.CrossRefPubMed

48.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169(6):1310–3.CrossRefPubMed

49.

Sachse MM, Wagner G. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids. Br J Dermatol. 2014;170(2):475–7.CrossRefPubMed

50.

Anforth R, Fernandez-Penas P. BRAF inhibitor induced verrucal keratosis. Am J Dermatopathol. 2014;36(2):192.CrossRefPubMed

51.

Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012;25(5):569–72.CrossRefPubMed

52.

Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.CrossRefPubMedPubMedCentral

53.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.CrossRefPubMedPubMedCentral

54.

Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448–9.CrossRefPubMed

55.

Gerami P, Sorrell J, Martini M. Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib. J Am Acad Dermatol. 2012;67(6):e275–6.CrossRefPubMed

56.

Haenssle HA, Kraus SL, Brehmer F, Kretschmer L, Völker B, Asper H, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148(10):1183–5.CrossRefPubMed

57.

Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier P-P, Duru G, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134(5):1351–8.CrossRefPubMed

58.

Carrera C, Puig-Butillè JA, Tell-Marti G, García A, Badenas C, Alós L, et al. Multiple BRAF wild-type melanomas during dabrafenib treatment for metastatic BRAF-mutant melanoma. JAMA Dermatol. 2015;151(5):544–8.CrossRefPubMed

59.

Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF Inhibition. J Clin Oncol. 2012;30(19):2375–83.CrossRefPubMedPubMedCentral

60.

Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, et al. BRAF inhibitor therapy—associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016;50:79–89.CrossRefPubMed

61.

Dalle S, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, et al. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol. 2013;149(4):488–90.CrossRefPubMed

62.

Loewe R, Kittler H, Fischer G, Faé I, Wolff K, Petzelbauer P. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol. 2004;123:733–6.CrossRefPubMed

63.

Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–4.CrossRefPubMed

64.

Kumar R, Angelini S, Snellman E, Kemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–8.CrossRefPubMed

65.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10(7):390–9.CrossRefPubMedPubMedCentral

66.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71(6):1102–9 (e1).CrossRefPubMedPubMedCentral

67.

Erfan G, Puig S, Carrera C, Arance A, Gaba L, Victoria I, et al. Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors. Acta Derm Venereol. 2017;97(2):258–60.CrossRefPubMed

68.

Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137–44.CrossRefPubMed

69.

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250–4.CrossRefPubMed

70.

Abdel-Rahman O, Elhalawani H, Ahmed H. Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. Clin Transl Oncol. 2016;18(8):848–58.CrossRefPubMed

71.

Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.CrossRefPubMed

72.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591–8.CrossRefPubMed

73.

Vennepureddy A, Thumallapally N, Motilal V. Novel drugs and combination therapies for the treatment of metastatic melanoma. J Clin Med Res. 2016;8(2):63–75.CrossRefPubMed

74.

Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221–36.CrossRefPubMed

75.

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.CrossRefPubMedPubMedCentral

76.

Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.CrossRefPubMedPubMedCentral

77.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRefPubMed

78.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.CrossRefPubMedPubMedCentral

79.

Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61 (e1).CrossRefPubMed

80.

Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–8.CrossRefPubMed

81.

Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18–22.CrossRefPubMed

82.

Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708–20.CrossRefPubMedPubMedCentral

83.

Sullivan RJ, Flaherty KT. Pembrolizumab for treatment of patients with advanced or unresectable melanoma. Clin Cancer Res. 2015;21(13):2892–7.CrossRefPubMed

84.

Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61.CrossRefPubMed

85.

Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death—1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–70.CrossRefPubMed

86.

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.CrossRefPubMed

87.

Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–6.CrossRefPubMed

88.

Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol. 2017;153(11):1162–5.CrossRefPubMedPubMedCentral

89.

Hwang SJE, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26(4):413–6.CrossRefPubMed

90.

Le Naour S, Peuvrel L, Saint-Jean M, Dreno B, Quereux G. Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. J Eur Acad Dermatol Venereol. 2018;32(3):e104–6.CrossRefPubMed

91.

Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 2015;151(7):797–9.CrossRefPubMed

92.

Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al. Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254–7.CrossRefPubMed

93.

Sahuquillo-Torralba A, Ballester-Sánchez R, Pujol-Marco C, Botella-Estrada R. Pembrolizumab: a new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr. 2016;107(3):264–6.CrossRefPubMed

94.

Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016;30(10):e89–91.CrossRefPubMed

95.

Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–78.CrossRefPubMed

96.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017;153(7):694.CrossRefPubMedPubMedCentral

97.

Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.CrossRefPubMed

98.

Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced grover disease. Br J Dermatol. 2014;171(5):1236–7.CrossRefPubMed

99.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, et al. Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol. 2017;44(12):1080–6.CrossRefPubMed

Titel: Cutaneous toxicities of new treatments for melanoma
verfasst von: A. Boada
C. Carrera
S. Segura
H. Collgros
P. Pasquali
D. Bodet
S. Puig
J. Malvehy
Publikationsdatum: 24.05.2018
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 11/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1891-7

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cutaneous toxicities of new treatments for melanoma

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma

Radiotherapy volume delineation using 18F-FDG-PET/CT modifies gross node volume in patients with oesophageal cancer

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial

Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer

Are endometrial cancer radiotherapy results age related?

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie